Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma - PubMed (original) (raw)
Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma
Noboru Nakaigawa et al. Cancer Res. 2006.
Abstract
It is well known that inactivation of von Hippel-Lindau (VHL) gene predisposes for human clear cell renal carcinoma (CCRC). However, details about critical roles of VHL inactivation during tumorigenesis are still unknown. MET protein is a tyrosine kinase receptor for hepatocyte growth factor/scatter factor (HGF/SF), which regulates cell growth, cell morphology, and cell motility. We showed that MET protein overexpressed in CCRC cells was phosphorylated without HGF/SF. This constitutive phosphorylation of MET protein in CCRC cells was inhibited by the rescue of exogenous wild-type VHL gene without a decrease in expression level of MET protein. Interestingly, wild-type VHL gene suppressed the phosphorylation of MET protein only under high cell density conditions. Additionally, MET protein activated by the inactivation of VHL gene modified cell adherence, including N-cadherin and beta-catenin. When activation of MET protein in CCRC cells was inhibited by the MET inhibitor K252a, the growth of CCRC cells in vitro and the tumorigenesis induced by CCRC cells in nude mice were suppressed. From these results, we concluded that inactivation of VHL gene induced constitutive phosphorylation of MET protein and modified intercellular adherence structure to trigger the cell growth released from contact inhibition, finally resulting in tumorigenesis. This is one of the mechanisms of CCRC oncogenesis, and MET protein has potential as a molecular target for novel CCRC therapies.
Similar articles
- Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP, Currie MJ, Han C, Turner K, Scott PA, Robinson BA, Harris AL, Fox SB. Gunningham SP, et al. Cancer Res. 2001 Apr 1;61(7):3206-11. Cancer Res. 2001. PMID: 11306510 - Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F, Maher ER. Morris MR, et al. Cancer Res. 2005 Jun 1;65(11):4598-606. doi: 10.1158/0008-5472.CAN-04-3371. Cancer Res. 2005. PMID: 15930277 - Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU. Wiesener MS, et al. Cancer Res. 2001 Jul 1;61(13):5215-22. Cancer Res. 2001. PMID: 11431362 - The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG Jr. Kaelin WG Jr. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. doi: 10.1158/1078-0432.CCR-sup-040025. Clin Cancer Res. 2004. PMID: 15448019 Review. - Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM, Vasselli J, Srinivasan R, Walther MM, Merino M, Choyke P, Vocke C, Schmidt L, Isaacs JS, Glenn G, Toro J, Zbar B, Bottaro D, Neckers L. Linehan WM, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6282S-9S. doi: 10.1158/1078-0432.CCR-050013. Clin Cancer Res. 2004. PMID: 15448018 Review.
Cited by
- Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling.
Makino K, Kawamura K, Sato W, Kawamura N, Fujimoto T, Terada Y. Makino K, et al. PLoS One. 2012;7(7):e41049. doi: 10.1371/journal.pone.0041049. Epub 2012 Jul 23. PLoS One. 2012. PMID: 22911740 Free PMC article. - Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines.
Khurana A, Tun HW, Marlow L, Copland JA, Dredge K, Shridhar V. Khurana A, et al. Mol Carcinog. 2012 Jul;51(7):565-75. doi: 10.1002/mc.20824. Epub 2011 Jul 7. Mol Carcinog. 2012. PMID: 21739484 Free PMC article. - Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Hsieh JJ, et al. Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. Nat Rev Dis Primers. 2017. PMID: 28276433 Free PMC article. Review. - Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer.
Shulman M, Shi R, Zhang Q. Shulman M, et al. J Genet Genomics. 2021 Jul 20;48(7):552-559. doi: 10.1016/j.jgg.2021.05.016. Epub 2021 Jul 9. J Genet Genomics. 2021. PMID: 34376376 Free PMC article. Review. - Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma.
Nguyen CB, Oh E, Bahar P, Vaishampayan UN, Else T, Alva AS. Nguyen CB, et al. Cancers (Basel). 2024 Jan 31;16(3):601. doi: 10.3390/cancers16030601. Cancers (Basel). 2024. PMID: 38339352 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous